Sergio Giralt

1993–2025 年に発表

330
論文数
55,289
被引用数
125
h 指数
316
i10 指数

被引用数

Sergio Giralt の年別被引用数1948 年: 被引用 2 件1990 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 1 件1994 年: 被引用 5 件1995 年: 被引用 16 件1996 年: 被引用 30 件1997 年: 被引用 33 件1998 年: 被引用 51 件1999 年: 被引用 92 件2000 年: 被引用 137 件2001 年: 被引用 148 件2002 年: 被引用 224 件2003 年: 被引用 297 件2004 年: 被引用 184 件2005 年: 被引用 211 件2006 年: 被引用 205 件2007 年: 被引用 231 件2008 年: 被引用 240 件2009 年: 被引用 222 件2010 年: 被引用 315 件2011 年: 被引用 286 件2012 年: 被引用 293 件2013 年: 被引用 330 件2014 年: 被引用 289 件2015 年: 被引用 344 件2016 年: 被引用 348 件2017 年: 被引用 360 件2018 年: 被引用 360 件2019 年: 被引用 1,314 件2020 年: 被引用 1,701 件2021 年: 被引用 1,685 件2022 年: 被引用 1,283 件2023 年: 被引用 1,139 件2024 年: 被引用 1,919 件2025 年: 被引用 927 件2026 年: 被引用 27 件1949〜1989 年は被引用が無いため表示していません1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,642 件、この内訳の 29%ドイツ: 引用元論文 1,424 件、この内訳の 7.3%中国: 引用元論文 1,181 件、この内訳の 6.1%イタリア: 引用元論文 1,129 件、この内訳の 5.8%イギリス: 引用元論文 1,076 件、この内訳の 5.5%フランス: 引用元論文 1,044 件、この内訳の 5.4%スペイン: 引用元論文 840 件、この内訳の 4.3%オランダ: 引用元論文 684 件、この内訳の 3.5%カナダ: 引用元論文 615 件、この内訳の 3.2%日本: 引用元論文 436 件、この内訳の 2.2%オーストラリア: 引用元論文 425 件、この内訳の 2.2%スイス: 引用元論文 407 件、この内訳の 2.1%
0%29%その他 23.4%

分野

  • Medicine83.1%
  • Biochemistry, Genetics and Molecular Biology10.4%
  • Immunology and Microbiology4.6%
  • Engineering0.4%
  • Nursing0.2%
  • Agricultural and Biological Sciences0.2%
  • その他1.1%

トピック

  • Hematopoietic Stem Cell Transplantation9.4%
  • CAR-T cell therapy research8.2%
  • Multiple Myeloma Research and Treatments6.5%
  • Acute Myeloid Leukemia Research5.3%
  • Immune Cell Function and Interaction3.6%
  • Acute Lymphoblastic Leukemia research3%
  • その他64%

共著者

全論文

検索で開く
  1. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 705

  2. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michel Sadelain, Renier J. Brentjens - Science Translational Medicine 2014 被引用: 2,497

  3. GPRC5D-Targeted CAR T Cells for Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ahmet Doǧan, Ola Landgren, Sergio Giralt, Jae H. Park, Saad Z. Usmani, Isabelle Rivière, Renier J. Brentjens, Eric L. Smith - New England Journal of Medicine 2022 被引用: 384

  4. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nerea Castillo Flores, Ana Alarcón Tomás, Richard J. Lin, Lucrecia Yáñez, Gunjan L. Shah, Christina Cho, Michael Scordo, Ioannis Politikos, Kasumi Hayasaka, Yuta Hasegawa, Boglarka Gyurkocza, Doris M. Ponce, Juliet N. Barker, Miguel‐Angel Perales, Sergio Giralt, Robert R. Jenq, Takanori Teshima, Nelson J. Chao, Ernst Holler, João B. Xavier, Eric G. Pamer, Marcel R.M. van den Brink - New England Journal of Medicine 2020 被引用: 739

  5. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 被引用: 309

  6. Defining the Intensity of Conditioning Regimens: Working Definitions

    著者: , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2009 被引用: 1,797

  7. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam D. Cohen, Thomas H. Openshaw, Marcelo C. Pasquini, Sergio Giralt, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Amy Foley, Mariateresa Fulciniti, Kyle Hebert, Mehmet Samur, Kelly Masone, Michelle E. Maglio, Andrea A. Zeytoonjian, Omar Nadeem, Robert Schlossman, Jacob P. Laubach, Claudia E. Paba‐Prada, Irene M. Ghobrial, Aurore Perrot, Philippe Moreau, Hervé Avet‐Loiseau, Michel Attal, Kenneth C. Anderson, Nikhil C. Munshi - New England Journal of Medicine 2022 被引用: 463

  8. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation

    著者: , , , , , , , , , , , , , , - Blood 2014 被引用: 880

  9. Lactose drives Enterococcus expansion to promote graft-versus-host disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony D. Sung, Daigo Hashimoto, Christof Scheid, João B. Xavier, Julia A. Messina, Kristi Romero, M. Lew, Amy Bush, Lauren Bohannon, Kasumi Hayasaka, Yuta Hasegawa, Maria J. G. T. Vehreschild, Justin R. Cross, Doris M. Ponce, Miguel‐Angel Perales, Sergio Giralt, Robert R. Jenq, Takanori Teshima, Ernst Holler, Nelson J. Chao, Eric G. Pamer, Jonathan U. Peled, Marcel R.M. van den Brink - Science 2019 被引用: 369

  10. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 442

  11. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2020 被引用: 264

  12. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 被引用: 496

  13. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 被引用: 762

  14. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 666

  15. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2021 被引用: 198

  16. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric G. Pamer, João B. Xavier - Science Translational Medicine 2018 被引用: 373

  17. Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

    著者: , , , , , , - Biology of Blood and Marrow Transplantation 2009 被引用: 901

  18. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 168

  19. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 103

  20. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan H. Hsu, Aisha Hasan, Richard J. O’Reilly - Journal of Clinical Investigation 2019 被引用: 229

  21. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 被引用: 376

  22. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Abraham Avigdor, Miguel‐Angel Perales, Roni Shouval - Leukemia 2022 被引用: 102

  23. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Weisdorf, Juan Wu, Marcelo C. Pasquini, John Koreth - The Lancet Haematology 2019 被引用: 281

  24. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy

    著者: , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2020 被引用: 274